Connect Biopharma Holdings Limited Short Interest Update
CNTB Stock | USD 0.97 0.01 1.02% |
About 61% of Connect Biopharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Connect Biopharma Holdings suggests that many traders are alarmed. The current market sentiment, together with Connect Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Connect Biopharma stock news signals to limit their universe of possible portfolio assets.
Connect |
Connect Biopharma Holdings Limited was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 22,700 shares, a drop of 22.8 percent from the October 31st total of 29,400 shares. Currently, 0.0 percent of the shares of the company are sold short.
Read at thelincolnianonline.com
Connect Biopharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Connect Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Connect Biopharma Fundamental Analysis
We analyze Connect Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Connect Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Connect Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Connect Biopharma is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Connect Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Connect Biopharma stock to make a market-neutral strategy. Peer analysis of Connect Biopharma could also be used in its relative valuation, which is a method of valuing Connect Biopharma by comparing valuation metrics with similar companies.
Peers
Connect Biopharma Related Equities
SCPH | Scpharmaceuticals | 5.57 | ||||
MIST | Milestone Pharmaceuticals | 0.54 | ||||
LUMO | Lumos Pharma | 0.47 | ||||
MCRB | Seres Therapeutics | 1.12 | ||||
ELYM | Eliem Therapeutics | 2.91 |
Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |